Gary Glick, a chemist and very well-recognized biotech entrepreneur, has lifted far more than $200 million to start the most up-to-date organization aiming to harness advancements in medicinal chemistry to invent new medicines for cancer and inflammatory disorders.

Named Odyssey Therapeutics, the startup is backed by OrbiMed Advisors, SR A single Capital Administration and 50 % a dozen other undertaking funds firms that collectively staked Glick and his workforce with the sizable Series A financing spherical.

For now, Odyssey isn’t revealing a great deal about the illnesses or targets it hopes to go soon after, even though its funding has allowed the corporation to sketch out seven drug discovery courses. The biotech’s aim, Glick said in an job interview, is to progress among a single and 3 drug candidates into clinical testing by the close of 2023 or early 2024.

To help attain that intention, Glick has assembled a veteran group of drug hunters that involves Shifeng Pan, director of discovery chemistry at the Genomics Institute of the Novartis Study Foundation for the past 8 yrs. Pan, who was Odyssey’s to start with employ, aided find out the cancer medications Braftovi and Odomzo, as effectively as Novartis’ new many sclerosis remedy Mayzent.

Joining Glick and Pan are Robert Abraham, most not too long ago the main scientific officer at Vividion Therapeutics and previously the head of oncology R&D at Pfizer Natalie Dales, formerly head of portfolio and approach for Novartis’ discovery chemistry group and Joseph McDonald, who’s worked as an govt responsible for device learning and physics-based mostly simulation at Bristol Myers Squibb and Celgene.

“These are people who have observed so much,” Glick mentioned. “We have set jointly a staff that arguably could be a senior workforce and a discovery group at any key pharma.”

In accordance to Glick, the team’s practical experience assisted Odyssey increase its sizable funding round. At $218 million, Odyssey’s funding is one of the major Sequence A’s for a biotech this 12 months and various times bigger than the $60 million typical funding for cancer drug startups, in accordance to info from Consider Vantage.

The economical backing has also assisted Odyssey rapidly use nearly 100 staff because…